



ABSTRACT SUBMISSION

Abstract deadline **October 29th 2010**

You may apply and submit your abstract to the organising secretariat online at: www.cnio.es/events

Only papers whose abstracts have been reviewed and approved by the conference coordinators will be presented.

Abstracts should be written in English and the text should not exceed 2000 characters (or 450 words), title included.

CANCELLATION OF REGISTRATION

In case of cancellation without replacement, the fee less handling charges of 60 € will be refunded.

OFFICIAL LANGUAGE

The official language of the conference will be English. No simultaneous translation will be provided.

CERTIFICATES

All participants will be issued with a certificate of attendance at the close of the conference.


BADGE

The badge is the only official evidence of registration and should be worn at all times during the conference. Loss of badge means loss of registration.

INSURANCE

The organisers bear no responsibility for untoward events in connection with, before, during and after the conference.

Participants are strongly advised to take out their own personal and travel insurance coverage.



CNIO FRONTIERS Meetings 2010

Spanish National Cancer
Research Centre



22-24 **November** 2010
Madrid

Cancer Pharmacogenetics: personalizing medicine

Organisers

Javier Benítez, CNIO, Madrid, Spain

William E. Evans, St. Jude Children's Research Hospital, Memphis, USA

Magnus Ingelman-Sundberg, Karolinska Institutet, Stockholm, Sweden

Miguel Martín, Hospital Gregorio Marañón, Madrid, Spain



For further information and to apply please go to www.cnio.es/events
Centro Nacional de Investigaciones Oncológicas (CNIO)
Melchor Fernández Almagro, 3 | 28029 Madrid | Spain

General Information

ORGANISING SECRETARIAT

Scientific Events Office
Spanish National Cancer Research Centre
Melchor Fernández Almagro, 3
28029 Madrid – Spain

CONFERENCE VENUE

Spanish National Cancer Research Centre
Melchor Fernández Almagro, 3
28029 Madrid – Spain

REGISTRATION AND ABSTRACT SUBMISSION AVAILABLE AT:
www.cnio.es/events

REGISTRATION

Registration may be carried out online (www.cnio.es/events). Registration fee is 200 €. Registration and payment must be processed by November 15th. The registration fee covers admission to the conference, an abstract book, coffee breaks and lunches throughout the conference as indicated in the programme.

CONFIRMATION OF REGISTRATION

Registration will only be confirmed upon receipt of the registration fee. Please note that the number of participants is limited to 100.

MONDAY, NOVEMBER 22

9:15-9:30 **Welcome address**

Javier Benítez, CNIO, Madrid, Spain

Session I: Inherited and somatic genetic variation and cancer pharmacotherapy

Chair: Rafael Rosell

9:30-10:05 **Magnus Ingelman-Sundberg**, Karolinska Institutet, Stockholm, Sweden
Pharmacogenetics and epigenetics of drug response

10:05-10:40 **Alex Sparreboom**, St. Jude Children's Research Hospital, Memphis, USA
Role of Polymorphic Transporters in Taxane Pharmacodynamics

10:40-11:15 **Julian Downward**, Cancer Research UK London Research Institute, London, UK
New approaches to targeting RAS signaling pathways in cancer

11:15-11:45 **Coffee break and poster session**

11:45-12:20 **Anna Di Rienzo**, The University of Chicago, Chicago, USA
Inter-individual and inter-ethnic variation in the transcriptional response to glucocorticoids

12:20-12:55 **Peter Campbell**, Wellcome Trust Sanger Institute, Cambridge, UK
Interrogating the architecture of cancer genomes

12:55-13:10 **Short talk #1**

13:10-13:25 **Short talk #2**

13:30-15:00 **Lunch and poster session**

Session II: Pharmacogenomic and epigenomic determinants of anti-cancer drug efficacy

Chair: Magnus Ingelman-Sundberg

15:00-15:35 **David A. Flockhart**, Indiana University School of Medicine, Indianapolis, USA
Clinical Pharmacogenomics in the Treatment of Breast Cancer

15:35-16:10 **Rafael Rosell**, Institut Català d'Oncologia (ICO), Barcelona, Spain
Personalizing targeted therapies in lung cancer

16:10-16:40 **Coffee break and poster session**

16:40-17:15 **Manel Esteller**, Bellvitge Biomedical Research Institute (IDIBELL), Barcelona, Spain
Pharmacoepigenetics and Epigenetic Drugs

17:15-17:30 **Short talk #3**

17:30-17:45 **Short talk #4**

TUESDAY, NOVEMBER 23

Session III: Pharmacogenetics of cancer adverse effects

Chair: William E. Evans

9:30-10:05 **William E. Evans**, St. Jude Children's Research Hospital, Memphis, USA
Pharmacogenomics of acute lymphoblastic leukemia in children

10:05-10:40 **Howard McLeod**, University of North Carolina, Chapel Hill, USA
Pharmacogenetics of colon cancer therapy

10:40-11:15 **Anna Gonzalez- Neira**, CNIO, Madrid, Spain
Pharmacogenetics in Breast Cancer Therapy

11:15-11:45 **Group picture, coffee break and poster session**

11:45-12:20 **Cristina Rodríguez-Antona**, CNIO, Madrid, Spain

Identification of genetic variants associated to the adverse effects of microtubule-targeted anticancer drugs

12:20-12:35 **Short talk #5**

12:35-12:50 **Short talk #6**

13:00-14:30 **Lunch and poster session**

Sesion IV: State-of-the-art in high-throughput technologies and bioinformatic tools for pharmacogenetics

Chair: Peter Campbell

14:30-15:05 **Jörg D. Hoheisel**, German Cancer Research Center (DKFZ), Heidelberg, Germany
Functional Genomics and Proteomics in Cancer Research

15:05-15:40 **Javier Benítez**, CNIO, Madrid, Spain
From Pharmacogenetics to Pharmacogenomics, the technological challenge

15:40-16:15 **Arcadi Navarro**, Universitat Pompeu Fabra, Barcelona, Spain
Genome-wide Association Studies Pipeline (GWASpi): a desktop application for genome-wide SNP analysis and management

16:15-16:45 **Coffee break and poster session**

16:45-17:20 **Teri E. Klein**, Stanford University Medical Center, Stanford, USA
PharmGKB: from Knowledge Acquisition to Clinical Applications

17:20-17:35 **Short talk #7**

17:35-17:50 **Short talk #8**

WEDNESDAY, NOVEMBER 24

Session V: Implementing Pharmacogenetics: how industry, regulators, clinicians and policymakers are shaping the field

Chair: Miguel Martín

9:30-10:05 **Miguel Martín**, Hospital Gregorio Marañón, Madrid, Spain
Pharmacogenetics: implications for the design of cancer clinical trials

10:05-10:40 **Ron Van Schaik**, Erasmus University Medical Center, Rotterdam, The Netherlands.
Barriers for pharmacogenetics implementation: a 6 year laboratory experience

10:40-11:15 **Christian Meisel**, Roche Pharma Research & Early Development
Fitting Treatments to Patients: implementing Personalized Healthcare in Oncology R&D

11:15-11:45 **Coffee break and poster session**

11:45-12:20 **Bruno Flamion**, Scientific Advise Committee, European Medicines Agency, London, UK
Regulatory agencies

12:20 **Closing remarks and poster prize**

Magnus Ingelman-Sundberg, Karolinska Institutet, Stockholm, Sweden

Note: Talks: 25 minutes **Discussion:** 10 minutes after each talk

8 Short talks 10 minutes each **Discussion:** 5 minutes after each short talk.

8 short talks will be selected from the submitted abstracts

Abstracts should only be submitted via on-line